Access the world's leading financial data and tools

Subscribe for $2
Overview
Profile

Cryosite stock

CTE.AX
AU000000CTE1
621943

Price

0.85
Today +/-
+0
Today %
+0 %

Cryosite stock price

%
Weekly
Details

Price

ⓘ

Overview

The Quote Chart provides detailed and dynamic insights into the Cryosite stock's performance, showcasing daily, weekly, or monthly aggregated quotes. Users can switch between different time frames to analyze the stock's progression meticulously and make informed investment decisions.

Intraday Feature

The intraday feature provides real-time data, allowing investors to view the Cryosite stock’s price fluctuations within the trading day, facilitating timely and strategic investment decisions.

Total Return and Relative Price Change

View the total return of the Cryosite stock to gauge its profitability over time. The relative price change, based on the first quote available in the selected timeframe, offers insights into the stock’s performance, assisting in evaluating its investment potential.

Interpretation and Investment

Utilize the comprehensive data presented in the Quote Chart to analyze Cryosite's market trends, price movements, and potential returns. Make informed investment choices by comparing different time frames and evaluating intraday data for optimized portfolio management.

Cryosite Stock Price History

DateCryosite Price
12/17/20240.85 undefined
12/13/20240.85 undefined
12/12/20240.80 undefined
12/5/20240.85 undefined
12/2/20240.89 undefined
11/28/20240.85 undefined
11/27/20240.85 undefined
11/22/20240.90 undefined
11/21/20240.86 undefined

Cryosite Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Cryosite, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Cryosite from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Cryosite’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Cryosite. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Cryosite’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Cryosite’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Cryosite’s growth potential.

Cryosite Revenue, EBIT and net profit per share

DateCryosite RevenueCryosite EBITCryosite Net Income
202412.61 M undefined2.05 M undefined1.84 M undefined
202311.94 M undefined1.52 M undefined1.41 M undefined
202211.76 M undefined1.88 M undefined1.36 M undefined
202110.02 M undefined1.21 M undefined652,570 undefined
20209.01 M undefined806,520 undefined1.48 M undefined
20197.97 M undefined42,590 undefined-1.72 M undefined
20185.92 M undefined318,370 undefined-1.24 M undefined
20175.88 M undefined-20,760 undefined225,100 undefined
201610.14 M undefined439,260 undefined302,470 undefined
20159.84 M undefined608,990 undefined455,170 undefined
20149.42 M undefined680,000 undefined510,000 undefined
20138.76 M undefined1.19 M undefined1.25 M undefined
20128.02 M undefined1.03 M undefined1.02 M undefined
20116.66 M undefined320,000 undefined330,000 undefined
20106.14 M undefined30,000 undefined0 undefined
20096.32 M undefined-200,000 undefined10,000 undefined
20086.69 M undefined460,000 undefined450,000 undefined
20074.9 M undefined380,000 undefined920,000 undefined
20064.25 M undefined110,000 undefined100,000 undefined
20053.06 M undefined-610,000 undefined-620,000 undefined

Cryosite Income Statement, Balance Sheet, Cash Flow Statement

  • Simple

  • Expanded

  • Income Statement

  • Balance Sheet

  • Cashflow

 
REVENUE (M)REVENUE GROWTH (%)GROSS MARGIN (%)GROSS INCOME (M)NET INCOME (k)NET INCOME GROWTH (%)DIV. ()DIV. GROWTH (%)SHARES (M)DOCUMENTS
200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024
00223446666889910557910111112
----50.0033.33-50.00---33.33-12.50-11.11-50.00-40.0028.5711.1110.00-9.09
--350.00350.0033.3350.0050.0050.0050.0033.3350.0050.0050.0044.4455.5640.0060.0060.0042.8644.4450.0054.5563.6458.33
000012233234445433345677
-1,000-1,000-1,000000000001,0001,0000000-1,000-1,0001,00001,0001,0001,000
--------------------200.00----
------------------------
------------------------
16.316.335.3836.9845.0146.5247.9248.0146.6446.6447.1647.1646.6447.1647.1646.9846.8646.8646.8648.8146.8648.8148.8148.81
------------------------
Details

Keystats

ⓘ

Revenue and Growth

The Cryosite Revenue and Revenue Growth are pivotal to understanding the company's financial health and operational efficiency. A consistent increase in revenue indicates a company’s ability to effectively market and sell its products or services, while the revenue growth percentage offers insights into the pace at which the company is expanding over the years.

Gross Margin

The Gross Margin is a crucial metric that showcases the percentage of revenue exceeding the cost of goods sold (COGS). A higher gross margin is indicative of a company’s efficiency in controlling its production costs, thereby promising potential profitability and financial stability.

EBIT and EBIT Margin

EBIT (Earnings Before Interest and Taxes) and EBIT Margin offer deep insights into a company’s profitability, excluding the impacts of interest and taxes. Investors often assess these metrics to gauge the operational efficiency and inherent profitability of a business, separate from its financial structure and tax environment.

Income and Growth

Net Income and its subsequent growth are quintessential for investors looking to understand a company’s profitability. Consistent income growth underscores a company’s ability to enhance its profitability over time, reflecting operational efficiency, strategic competitiveness, and financial health.

Shares Outstanding

Shares outstanding refer to the total number of shares a company has issued. It's instrumental in calculating key metrics like Earnings Per Share (EPS) which is pivotal for investors to evaluate a company’s profitability on a per-share basis, offering a more granular view of financial health and valuation.

Interpreting Year to Year Comparison

Comparing yearly data allows investors to identify trends, assess the company’s growth, and anticipate potential future performance. Analyzing how metrics like revenue, income, and margins change year over year can provide valuable insights into the company’s operational efficiency, competitiveness, and overall financial health.

Expectations and Predictions

Investors often juxtapose the current and past financial data with the market’s expectations. This comparison aids in assessing whether the Cryosite is performing as anticipated, underperforming or outperforming the market predictions, providing pivotal data for investment decisions.

 
ASSETSCASH BALANCE (M)RECEIVABLES (M)OTHER REC. (k)INVENTORIES (k)OTHER CURRENT LIAB. (M)CURRENT ASSETS (M)TANGIBLE ASSETS (M)LONG-T. INVEST. (k)LONG-T. REC. (M)INTANGIBLE ASSETS (M)GOODWILL (M)OTHER NON-CURRENT ASSETS (M)NON-CURRENT ASSETS (M)TOTAL ASSETS (M)LIABILITIESCOMMON STOCK (M)ADDITIONAL PAID-IN CAPITAL (M)RETAINED EARNINGS (M)OTHER EQUITY (M)UNREAL. GAINS/LOSSES (M)EQUITY (M)LIABILITIES (M)PROVISIONS (k)OTHER SHORT-TERM LIAB. (M)SHORT-TERM DEBTS (M)LONG-TERM DEBT PORTION (k)SHORT-TERM REC. (M)LONG-T. LIAB. (M)DEFERRED TAXES (M)OTHER LIAB. (M)LONG-T. LIABILITIES (M)DEBT (M)TOTAL CAPITAL (M)
200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024
                                               
0.492.91.642.081.351.31.581.981.332.052.914.525.786.254.173.655.094.693.924.063.885.345.734.7
00.20.460.490.610.771.081.471.261.011.0911.451.771.752.882.311.360.840.961.671.211.731.36
3080508017030025021014016016016019013000021.6829.08000045
201020202030305050503050706090.46119.9981.5723.8522.8647.8852.51476059
0.030.050.10.150.140.140.190.130.250.040.160.260.380.140.260.290.130.292.141.851.691.71.661.57
0.573.242.272.822.292.543.133.843.033.314.355.997.878.356.276.947.616.386.956.937.298.39.187.74
1.131.11.141.051.20.890.820.942.012.192.3821.791.621.461.210.920.620.392.382.152.44.041.45
000000018018018000000000000000
0.030.030.120.541.181.641.551.471.371.251.1210.860.80.560.640.530.240.190.140.08000
000000.050.350.28000000.260.390.560.560.060.010.020.020.010.012.26
000000000000000000000000
0000000.550.550.760.750.780.780.850.60.450.310.20.4415.6414.0412.4510.789.428.26
1.161.131.261.592.382.583.273.424.324.374.283.783.53.282.862.722.211.3616.2316.5814.713.213.4711.98
1.734.373.534.414.675.126.47.267.357.688.639.7711.3711.639.129.669.837.7423.1723.521.9921.522.6519.71
                                               
06.636.687.827.828.048.048.148.148.148.148.148.148.25.865.865.865.865.865.865.865.985.983.54
000000000000000000000000
-1.52-2.74-3.91-4.78-5.34-5.22-4.3-3.82-3.8-3.78-3.45-2.66-1.87-2.07-2.32-2.48-2.71-3.92-7.58-6.15-5.48-4.12-3.2-2.09
2.8300000000000000000000000
000000000000000000000000
1.313.892.773.042.482.823.744.324.344.364.695.486.276.133.543.383.151.94-1.72-0.290.381.862.781.45
0.020.340.450.610.750.390.440.480.460.330.430.440.720.480.881.111.090.460.880.730.790.921.251.15
000000001702103003604604500000000280262284
0.390.080.060.150.250.340.750.930.860.881.030.960.881.010.880.850.830.692.482.442.482.522.262.56
000000000000000000000000
0000000000000000000197.3215.25000
0.410.420.510.7610.731.191.411.491.421.761.762.061.941.761.961.911.143.353.373.483.733.783.99
0.010000000000000000001.070.850.622.452.27
000000000000000000000000
00.050.250.61.191.571.471.521.521.912.162.533.033.563.824.324.774.6621.5319.3617.2915.313.6412.01
0.010.050.250.61.191.571.471.521.521.912.162.533.033.563.824.324.774.6621.5320.4218.1415.9216.0914.27
0.420.470.761.362.192.32.662.933.013.333.924.295.095.55.586.286.685.824.8923.7921.6219.6419.8718.26
1.734.363.534.44.675.126.47.257.357.698.619.7711.3611.639.129.669.837.7423.1723.521.9921.522.6519.71
Details

Balance Sheet

ⓘ

Understanding the Balance Sheet

The balance sheet of Cryosite provides a detailed financial snapshot, revealing the company's assets, liabilities, and equity at a specific point in time. Analyzing these components is crucial for investors looking to understand Cryosite's financial health and stability.

Assets

Cryosite's assets represent everything the company owns or controls that has monetary value. These are categorized into current and non-current assets, offering insights into the company's liquidity and long-term investments.

Liabilities

Liabilities are obligations that Cryosite must settle in the future. Analyzing the ratio of liabilities to assets provides insights into the company's financial leverage and risk exposure.

Equity

Equity refers to the residual interest in the assets of Cryosite after deducting liabilities. It represents the owners’ claim on the company’s assets and earnings.

Year-to-Year Analysis

Comparing balance sheet figures year-to-year allows investors to identify trends, growth patterns, and potential financial risks, facilitating informed investment decisions.

Interpreting the Data

Detailed analysis of assets, liabilities, and equity can provide investors with comprehensive insights into Cryosite's financial standing, aiding in investment evaluations and risk assessments.

 
NET INCOME (k)DEPRECIATION (M)DEFERRED TAXES (M)CHANGES IN WORKING CAPITAL (k)NON-CASH ITEM (M)PAID INTEREST (M)PAID TAXES (M)NET CASH FLOW FROM OPERATING ACTIVITIES (M)CAPITAL EXPENDITURES (M)CASH FLOW FROM INVESTING ACTIVITIES (M)CASH FLOW FROM OTHER INVESTING ACTIVITIES (M)INTEREST INCOME AND EXPENSES (M)NET DEBT CHANGE (M)NET CHANGE IN EQUITY (M)CASH FLOW FROM FINANCING ACTIVITIES (M)CASH FLOW FROM OTHER FINANCING ACTIVITIES ()TOTAL DIVIDENDS PAID (M)NET CHANGE IN CASH FLOW (M)FREE CASH FLOW (M)SHARE-BASED COMPENSATION (M)
2002200320042005200620072008200920102011201220132014201520162017201820192020202120222023
0000000000000000000001,000
0000000000000000000000
0000000000000000000000
0000000000000000001,000000
0000000000000000000000
0000000000000000000000
0000000000000000000000
-1000000001111101001021
0000000-100000000000000
0000000-10000000000000-1
0000000000000000000000
0000000000000000000000
0000000000000000000000
4010000000000000000000
3010000000000-300000000
--------------2.00--------
0000000000000000000000
1-20-10010123320030-10030
-1.4-1.27-0.93-0.66-0.260.280.39-0.650.710.721.71.560.860.79-0.111.33-0.44-0.670.410.121.661.11
0000000000000000000000

Cryosite stock margins

The Cryosite margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Cryosite. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Cryosite.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Cryosite's sales revenue. A higher gross margin percentage indicates that the Cryosite retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Cryosite's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Cryosite's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Cryosite's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Cryosite. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Cryosite's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Cryosite Margin History

Cryosite Gross marginCryosite Profit marginCryosite EBIT marginCryosite Profit margin
202463.38 %16.29 %14.59 %
202360.11 %12.77 %11.81 %
202258.16 %16 %11.6 %
202158.8 %12.08 %6.51 %
202044.85 %8.95 %16.42 %
201942.26 %0.53 %-21.6 %
201857.2 %5.38 %-20.94 %
201751.25 %-0.35 %3.83 %
201640.6 %4.33 %2.98 %
201551.17 %6.19 %4.62 %
201451.59 %7.22 %5.41 %
201353.65 %13.58 %14.27 %
201251.25 %12.84 %12.72 %
201148.65 %4.8 %4.95 %
201046.58 %0.49 %0 %
200949.84 %-3.16 %0.16 %
200850.97 %6.88 %6.73 %
200752.45 %7.76 %18.78 %
200650.35 %2.59 %2.35 %
200543.79 %-19.93 %-20.26 %

Cryosite Stock Sales Revenue, EBIT, Earnings per Share

The Cryosite earnings per share therefore indicates how much revenue Cryosite has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Sales per Share
EBIT per share
Earnings per Share
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Cryosite earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Cryosite's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Cryosite’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Cryosite's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Cryosite Revenue, EBIT and net profit per share

DateCryosite Sales per ShareCryosite EBIT per shareCryosite Earnings per Share
20240.26 undefined0.04 undefined0.04 undefined
20230.24 undefined0.03 undefined0.03 undefined
20220.24 undefined0.04 undefined0.03 undefined
20210.21 undefined0.03 undefined0.01 undefined
20200.18 undefined0.02 undefined0.03 undefined
20190.17 undefined0 undefined-0.04 undefined
20180.13 undefined0.01 undefined-0.03 undefined
20170.13 undefined-0 undefined0 undefined
20160.22 undefined0.01 undefined0.01 undefined
20150.21 undefined0.01 undefined0.01 undefined
20140.2 undefined0.01 undefined0.01 undefined
20130.19 undefined0.03 undefined0.03 undefined
20120.17 undefined0.02 undefined0.02 undefined
20110.14 undefined0.01 undefined0.01 undefined
20100.13 undefined0 undefined0 undefined
20090.14 undefined-0 undefined0 undefined
20080.14 undefined0.01 undefined0.01 undefined
20070.1 undefined0.01 undefined0.02 undefined
20060.09 undefined0 undefined0 undefined
20050.07 undefined-0.01 undefined-0.01 undefined

Cryosite business model

Cryosite Ltd was founded in Australia in 1999 and has since become a leading provider of services in the field of biological sample storage. The company specializes in the storage of blood, bone marrow, tissue, and other biological samples. Based in Sydney, Cryosite Ltd operates branches throughout Australia and is increasingly expanding into international business. Cryosite Ltd's business model is based on providing secure and reliable storage solutions for biological samples. This includes the collection, processing, and storage of biological samples, as well as their transportation and traceability. Cryosite Ltd offers its customers a comprehensive range of services to facilitate the storage and shipment of biological samples. This includes the development of customized archiving solutions tailored to individual needs. The company's various divisions include archiving solutions, clinical trials, stem cell therapy, biobanking, and blood banks. Cryosite Ltd's archiving solutions involve the setup, maintenance, and monitoring of biological samples in engraved tubes and boxes. The company offers a variety of cryopreservation systems to ensure that samples are stored under optimal conditions and can be retrieved within a specified timeframe. Additionally, the company also provides digital archiving solutions that enable efficient management and retrieval of stored data. Cryosite Ltd is also involved in clinical trials by assisting companies in conducting clinical studies. The company provides the necessary logistics and sample management to ensure that samples are properly processed, stored, and returned. It also provides comprehensive documentation to ensure the highest compliance standards. In the field of stem cell therapy, Cryosite Ltd offers a wide range of services that enable companies and researchers to store and process stem cells under optimal conditions. The company specializes in providing a wide range of application-oriented solutions and is a leader in the industry in supporting customers in the use of these technologies to enhance diagnostic and therapeutic discoveries. In the field of biobanking, Cryosite Ltd offers a comprehensive range of services to research institutes and organizations. Biobanking services include the setup, storage, monitoring, and tracking of biological samples for future research purposes. The company also offers services for the biobanking of clinical samples for disease diagnosis and evaluation. The company also operates blood banks that focus on blood donation and storage of blood products for efficient availability to patients. It offers a wide range of blood bank products and services to ensure effective blood supply for patients. Cryosite Ltd is committed to providing its customers with the highest standards in the storage and handling of blood products. In summary, Cryosite Ltd is a leading provider of storage and processing services for biological samples. The company has a long history of providing solutions for a wide range of applications in medical research and the medical industry. It strives to meet the highest standards and ensure that all samples are processed and stored efficiently and safely. Cryosite Ltd stays up to date with the latest technology and advanced processes to handle samples with maximum efficiency and quality. Cryosite is one of the most popular companies on Eulerpool.com.

Cryosite SWOT Analysis

Strengths

1. Cryosite Ltd has a strong reputation as a leader in the field of cryogenic storage and services.

2. The company possesses state-of-the-art facilities and technological expertise, ensuring high-quality and reliable cryopreservation solutions.

3. Cryosite Ltd has a diversified customer base, including pharmaceutical companies, research institutions, and healthcare organizations.

Weaknesses

1. The company heavily relies on the stability of its customer relationships, making it susceptible to potential loss of clients.

2. Cryosite Ltd's services are highly specialized and may be more expensive compared to competitors, potentially limiting market share.

3. There may be regulatory challenges related to the cryopreservation industry that could affect the company's operations.

Opportunities

1. Increasing demand for cryogenic storage is expected in various sectors, such as biotechnology and regenerative medicine, providing growth opportunities for Cryosite Ltd.

2. The company can expand its services to new geographic regions or target niche markets to capture additional market share.

3. Technological advancements in cryopreservation techniques may open doors for innovative product offerings by Cryosite Ltd.

Threats

1. Intense competition within the cryogenic storage industry poses a threat to Cryosite Ltd's market position and profitability.

2. Economic fluctuations and uncertain financial conditions can negatively impact customer spending, affecting demand for cryopreservation services.

3. Changes in regulations or legal frameworks governing cryogenic storage could impose compliance challenges and increase operating costs for the company.

LIMITED TIME OFFER

The World’s Best Investors Are On Eulerpool

Subscribe for $2

Cryosite Eulerpool Fair Value

Details

Fair Value

ⓘ

Understanding Fair Value

The fair value of a stock provides insights into whether the stock is currently undervalued or overvalued. It is calculated based on profit, revenue, or dividends and offers a comprehensive perspective of the stock’s intrinsic value.

Income-Based Fair Value

This is calculated by multiplying the earnings per share by the average P/E ratio of the selected past years for smoothing. If the fair value is higher than the current market price, it suggests that the stock is undervalued.

Example 2022

Fair Value Profit 2022 = Earnings per Share 2022 / Average P/E Ratio 2019 - 2021 (3 Years Smoothing)

Revenue-Based Fair Value

It is derived by multiplying the revenue per share by the average price-to-sales ratio of the selected past years for smoothing. An undervalued stock is identified if the fair value exceeds the ongoing market price.

Example 2022

Fair Value Revenue 2022 = Revenue per Share 2022 / Average PSR 2019 - 2021 (3 Years Smoothing)

Dividend-Based Fair Value

This value is determined by dividing the dividend per share by the average dividend yield of the selected past years for smoothing. A higher fair value than the market price indicates an undervalued stock.

Example 2022

Fair Value Dividend 2022 = Dividend per Share 2022 * Average Dividend Yield 2019 - 2021 (3 Years Smoothing)

Expectations and Forecasts

Future expectations provide potential trajectories for stock prices and aid investors in decision-making. The expected values are forecasted figures of fair value, taking into account the growth or decline trends of profit, revenue, or dividend.

Comparative Analysis

Comparing the fair value based on profit, revenue, and dividend provides a holistic overview of the stock’s financial health. Observing the annual and per-annual variations contributes to understanding the consistency and reliability of stock performance.

Cryosite historical P/E ratio, EBIT multiple, and P/S ratio

LIMITED TIME OFFER

The World’s Best Investors Are On Eulerpool

Subscribe for $2

Cryosite shares outstanding

The number of shares was Cryosite in 2023 — This indicates how many shares 48.81 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Cryosite earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Cryosite's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Cryosite’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Cryosite's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Cryosite dividend history and estimates

In 2023, Cryosite paid a dividend amounting to 0.02 AUD. Dividend means that Cryosite distributes a portion of its profits to its owners.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Dividend
Dividend (Estimate)
Details

Dividend

ⓘ

Dividend Overview

The dividend per year chart for Cryosite provides a comprehensive view of the annual dividends distributed to shareholders. Analyze the trend to understand the consistency and growth in dividend payouts over the years.

Interpretation and Use

A consistent or increasing trend in dividends can indicate the company's profitability and financial health. Investors can use this data to identify Cryosite’s potential for long-term investment and income generation through dividends.

Investment Strategy

Incorporate the dividend data in evaluating Cryosite's overall performance. A thorough analysis, considering other financial aspects, will help in making informed investment decisions for optimal capital growth and income generation.

Cryosite Dividend History

DateCryosite Dividend
20240.07 undefined
20230.02 undefined
20220.01 undefined
20170.01 undefined
20160.01 undefined
20150.01 undefined
20140.07 undefined
20130.02 undefined
20120.01 undefined

Cryosite dividend payout ratio

In 2023, Cryosite had a payout ratio of 60.75%. The payout ratio indicates the percentage of the company's profits that Cryosite distributes as dividends.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Payout ratio
Details

Payout ratio

ⓘ

What is Yearly Payout Ratio?

The yearly payout ratio for Cryosite represents the proportion of earnings paid out as dividends to shareholders. It is an indicator of the company's financial health and stability, illustrating how much profit is being returned to investors versus being reinvested back into the company.

How to Interpret the Data

A lower payout ratio for Cryosite could mean that the company is reinvesting more into its growth, whereas a higher ratio indicates more earnings are being distributed as dividends. Investors seeking regular income might prefer companies with a higher payout ratio, while those looking for growth may opt for companies with a lower ratio.

Using the Data for Investments

Evaluate Cryosite's payout ratio in conjunction with other financial metrics and performance indicators. A sustainable payout ratio, coupled with strong financial health, can indicate a reliable dividend payout. However, a very high ratio might suggest the company is not sufficiently reinvesting in its future growth.

Cryosite Payout Ratio History

DateCryosite Payout ratio
202455.4 %
202360.75 %
202235.78 %
202169.67 %
202076.81 %
201996.43 %
201898.23 %
2017-1,000 %
2016155.28 %
2015103.63 %
2014650 %
201350 %
201250 %
201198.23 %
201098.23 %
200998.23 %
200898.23 %
200798.23 %
200698.23 %
200598.23 %
LIMITED TIME OFFER

The World’s Best Investors Are On Eulerpool

Subscribe for $2
Unfortunately, there are currently no price targets and forecasts available for Cryosite.

Cryosite shareholders

%
Name
Stocks
Change
Date
19.93785 % Daltonvale Proprietary Ltd.9,731,66308/1/2024
18.43884 % Kerr (Mark Gregory)9,000,00008/1/2024
8.74021 % Robins Superfund Pty. Ltd.4,266,097144,9138/1/2024
6.48487 % Kroger (Andrew John)3,165,26308/1/2024
4.22045 % Strong (Alistair David)2,060,00035,0008/1/2024
4.09752 % Marensa Pty. Ltd.2,000,0002,000,0008/1/2024
2.18799 % Ginga Pty. Ltd.1,067,957500,0008/1/2024
2.04876 % BFA Super Pty. Ltd.1,000,00008/1/2024
1.85413 % Thirty Sixth Vilmar Pty Ltd905,000325,9018/1/2024
1.56281 % Mutual Trust Pty. Ltd.762,808762,8088/1/2024
1
2

Cryosite Executives and Management Board

Mr. Andrew Kroger

Cryosite Non-Executive Director
Compensation 81,938

Mr. Mark Kerr

Cryosite Non-Executive Chairman of the Board

Mr. John Hogg

Cryosite Chief Executive Officer, Managing Director

Ms. Dray Andrea

Cryosite Company Secretary
1

Most common questions regarding Cryosite

What values and corporate philosophy does Cryosite represent?

Cryosite Ltd is a leading company that values integrity, reliability, and innovation. With a strong corporate philosophy focused on providing premium services and solutions in the field of biobanking and reproductive services, Cryosite is committed to excellence. The company strives to ensure the utmost trust and transparency in all its operations, delivering high-quality cryopreservation services, cord blood banking, and stem cell research facilities. Cryosite Ltd continuously pushes boundaries through cutting-edge technology and strategic partnerships, aiming to meet the evolving needs of its customers and make a positive impact in the healthcare industry.

In which countries and regions is Cryosite primarily present?

Cryosite Ltd primarily operates in Australia and New Zealand.

What significant milestones has the company Cryosite achieved?

Cryosite Ltd has achieved several significant milestones. Firstly, the company successfully established itself as a leading provider of comprehensive storage solutions for stem cells, reproductive tissues, and cord blood in Australia. Additionally, Cryosite Ltd expanded its services by offering advanced cryopreservation techniques, ensuring the long-term viability of stored materials. The company's commitment to quality led to accreditation by the Therapeutic Goods Administration (TGA) and attainment of ISO 9001 certification. Furthermore, Cryosite Ltd expanded its client base, attracting partnerships with major healthcare institutions and research organizations. These milestones demonstrate Cryosite Ltd's success in delivering trusted and state-of-the-art cryogenic storage services to its clients.

What is the history and background of the company Cryosite?

Cryosite Ltd, a reputable Australian company, has an intriguing history and background. Established in 2000, Cryosite has played a pivotal role in the field of biomedical services. The company specializes in secure storage and transportation of precious biological samples, supporting medical research, clinical trials, and stem cell transplant programs. With state-of-the-art facilities and stringent quality control measures, Cryosite has gained recognition as a trusted partner for numerous healthcare institutions and research organizations globally. Over the years, Cryosite Ltd has showcased its expertise in preserving and managing these life-changing resources, contributing significantly to advancements in healthcare and cutting-edge research.

Who are the main competitors of Cryosite in the market?

The main competitors of Cryosite Ltd in the market are companies like Stemlife, Singapore Cord Blood Bank, and CordLife Group Limited.

In which industries is Cryosite primarily active?

Cryosite Ltd is primarily active in the biomedical and life sciences industries.

What is the business model of Cryosite?

The business model of Cryosite Ltd focuses on providing biobanking and cell therapy services. Cryosite specializes in the collection, storage, and distribution of human biological samples such as cord blood, tissue, and cells for medical and research purposes. The company allows individuals and families to preserve cord blood stem cells for potential future use in regenerative medicine. Cryosite also offers cell therapy manufacturing services to support personalized medicine and clinical trials. With its expertise and advanced technology, Cryosite aims to contribute to advancements in medical treatments and research, offering peace of mind to those seeking to preserve their biological materials.

What is the P/E ratio of Cryosite 2024?

The Cryosite P/E ratio is 22.55.

What is the P/S ratio of Cryosite 2024?

The Cryosite P/S ratio is 3.29.

What is the Quality Investing of Cryosite?

The Quality Investing for Cryosite is 5/10.

What is the revenue of Cryosite 2024?

The Cryosite revenue is 12.61 M AUD.

How high is the profit of Cryosite 2024?

The Cryosite profit is 1.84 M AUD.

What is the business model of Cryosite

Cryosite Ltd is an Australian company that has been operating in the field of biological material storage for over 15 years. With a wide range of services and products, the company has established itself as a leading provider of cryo-storage solutions in Australia.

What is the Cryosite dividend?

Cryosite pays a dividend of 0.01 AUD distributed over payouts per year.

How often does Cryosite pay dividends?

The dividend cannot currently be calculated for Cryosite or the company does not pay out a dividend.

What is the Cryosite ISIN?

The ISIN of Cryosite is AU000000CTE1.

What is the Cryosite WKN?

The WKN of Cryosite is 621943.

What is the Cryosite ticker?

The ticker of Cryosite is CTE.AX.

How much dividend does Cryosite pay?

Over the past 12 months, Cryosite paid a dividend of 0.07 AUD . This corresponds to a dividend yield of about 8.24 %. For the coming 12 months, Cryosite is expected to pay a dividend of 0.07 AUD.

What is the dividend yield of Cryosite?

The current dividend yield of Cryosite is 8.24 %.

When does Cryosite pay dividends?

Cryosite pays a quarterly dividend. This is distributed in the months of October, October, March, October.

How secure is the dividend of Cryosite?

Cryosite paid dividends every year for the past 3 years.

What is the dividend of Cryosite?

For the upcoming 12 months, dividends amounting to 0.07 AUD are expected. This corresponds to a dividend yield of 8.24 %.

In which sector is Cryosite located?

Cryosite is assigned to the 'Health' sector.

Wann musste ich die Aktien von Cryosite kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Cryosite from 10/10/2024 amounting to 0.02 AUD, you needed to have the stock in your portfolio before the ex-date on 9/6/2024.

When did Cryosite pay the last dividend?

The last dividend was paid out on 10/10/2024.

What was the dividend of Cryosite in the year 2023?

In the year 2023, Cryosite distributed 0.015 AUD as dividends.

In which currency does Cryosite pay out the dividend?

The dividends of Cryosite are distributed in AUD.

All fundamentals about Cryosite

Our stock analysis for Cryosite Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Cryosite Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.